BeiGene Stock-Based Compensation 2014-2024 | ONC
BeiGene annual/quarterly stock-based compensation history and growth rate from 2014 to 2024. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
- BeiGene stock-based compensation for the quarter ending September 30, 2024 was $0.334B, a 21.59% increase year-over-year.
- BeiGene stock-based compensation for the twelve months ending September 30, 2024 was $1.010B, a 21.36% increase year-over-year.
- BeiGene annual stock-based compensation for 2023 was $0.368B, a 21.26% increase from 2022.
- BeiGene annual stock-based compensation for 2022 was $0.303B, a 25.94% increase from 2021.
- BeiGene annual stock-based compensation for 2021 was $0.241B, a 31.19% increase from 2020.
BeiGene Annual Stock-Based Compensation
(Millions of US $) |
| 2023 |
$368 |
| 2022 |
$303 |
| 2021 |
$241 |
| 2020 |
$183 |
| 2019 |
$134 |
| 2018 |
$87 |
| 2017 |
$43 |
| 2016 |
$11 |
| 2015 |
$10 |
| 2014 |
$7 |
| 2013 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
